Science News & Science Current Events
 
Email a Friend Send to a friend
Printer Friendly Print Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients

Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients

June 16, 2008

Results from the ATTEST Trial

New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.




The ATTEST (Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA) trial compared abatacept (~10mg/kg), a selective T cell co-stimulation modulator, with infliximab (3mg/kg), a monoclonal antibody, plus methotrexate (as per each patient's usual dosage, mean dose 16.3-16.6mg) in 431 methotrexate-refractory patients, in a randomised, double-blind, placebo-controlled, 12-month study. Data analyses evaluated the proportion of patients who achieved a 20% improvement in symptoms (as defined by the American College of Rheumatology scale as an ACR20 response) at six months and went on to either improve, maintain or lose this score at twelve months. A similar analysis was conducted in relation to Low Disease Activity Score (LDAS) (DAS28 [CRP] ≤3.2).

ACR Response

Of those patients who achieved an ACR20 response at six months (32 abatacept [ABA] and 27 infliximab [IFX] patients), over a quarter of ABA and IFX patients went on to achieve a 50% improvement (ACR50) at one year (ABA 28.1%, IFX 29.6%). These ACR20 scores were maintained to one year in more ABA than INF patients (95% confidence interval, CI) with over half ABA patients sustained (ABA 59.4%, IFX 44.4%). Furthermore, half as many ABA patients lost their ACR20 score between six months and one year compared to IFX patients (ABA 12.5%, IFX 25.9%).

Low Disease Activity Score

In the LDAS analysis, it was shown that 24 ABA and 23 IFX patients achieved LDAS (but not remission) at six months. Of these patients, over a third ABA (41.7% [22.8, 63.1]) and a quarter IFX patients (28% [12.9, 49.6]) achieved remission at one year. A similar number of ABA (12.5% [3.3, 33.5]) and IFX patients (16% [5.3, 36.9]) retained LDAS to one year, whilst fewer ABA patients (45.8% [26.2, 66.9]) than IFX patients (56% [35.3, 75.0]) lost their LDAS score between six months and one year.

Lead researcher Dr Michael Schiff, of the University of Colorado, USA, commented: "Since RA is a chronic disease, long term treatment efficacy is crucial. Clinical rheumatologists and patients alike need to know the options for maintaining or even increasing treatment responses over time, especially with the growing problem of RA patients becoming refractory, or resistant, to existing treatments. Our study offers significant promise in showing that, where treatment with methotrexate as monotherapy is inadequate, both abatacept and infliximab provide an increasing magnitude of response in measures of RA disease activity, with abatacept yielding slightly higher results across some key ACR and LDAS scores."

European League Against Rheumatism



Related Infliximab Current Events and Infliximab News Articles Infliximab Current Events and Infliximab News RSS Infliximab Current Events and Infliximab News RSS
Mayo Clinic collaborates to advance Crohn's treatment
A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment.

'Stuffy nose' mouse: A promise to help treat 31 million with sinusitis
Mice with inflamed nasal tissue being tested at a Johns Hopkins laboratory may be unable to tell if something smells bad or good, but their sensory deficit is nothing to turn up a nose at.

New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).

New therapeutic targets in the treatment of ulcerative colitis
Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years.

Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients.

Promising drug fails to improve COPD symptoms
A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial.

New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE® (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75).

Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis
Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE® (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50.

Monoclonal antibody reduces exacerbations in asthmatics
Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo.
More Infliximab Current Events and Infliximab News Articles
RA response much improved by combo: infliximab-methotrexate.(Clinical Rounds): An article from: Family Practice News
by Diana Mahoney

This digital document is an article from Family Practice News, published by International Medical News Group on November 1, 2003. The length of the article is 721 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Infliximab Cut Psoriasis Severity Score by 75%.: An article from: Internal Medicine News
by Arnold Mann

This digital document is an article from Internal Medicine News, published by International Medical News Group on September 15, 2001. The length of the article is 829 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

No shortage of treatment options for IBD: use azathioprine before infliximab. (Clinical Rounds).(inflammatory bowel disease ): An article from: Family Practice News
by Bruce Jancin

This digital document is an article from Family Practice News, published by International Medical News Group on June 1, 2003. The length of the article is 1075 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Acute pulmonary edema during infliximab infusion.(Section on Internal Medicine): An article from: Southern Medical Journal
by Srinivas R. Puli, Martin A. Alpert, Vanaja Puli

This digital document is an article from Southern Medical Journal, published by Southern Medical Association on October 1, 2004. The length of the article is 489 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Pregnancy and Infliximab: Preliminary Results Indicate No Miscarriage Risk.: An article from: Internal Medicine News
by Nicholas Mulcahy

This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2001. The length of the article is 383 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Infliximab's Results Hold Steady Over Time.: An article from: Skin & Allergy News
by Betsy Bates

This digital document is an article from Skin & Allergy News, published by International Medical News Group on August 1, 2001. The length of the article is 1089 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Behcet's syndrome may respond to infliximab. (Six Cases).: An article from: Skin & Allergy News
by Nancy Walsh

This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2003. The length of the article is 5505 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Maintenance Doses of Infliximab can keep Crohn's in Remission. (Steroids often not needed).: An article from: Internal Medicine News
by Doug Brunk

This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2002. The length of the article is 669 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Life-threatening pustular and erythrodermic psoriasis responding to infliximab.(CASE REPORTS): An article from: Journal of Drugs in Dermatology
by Thomas G. Lewis, Chanisada Tuchinda, Henry W. Lim, Henry K. Wong

This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on June 1, 2006. The length of the article is 1665 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Infliximab safe in Crohn's with strictures, stenosis.(Digestive Disorders): An article from: Family Practice News
by Sharon Worcester

This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2005. The length of the article is 622 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com